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Metabolic Inhibition of Galectin-1-Binding
Carbohydrates Accentuates Antitumor Immunity
Filiberto Cedeno-Laurent1,2, Matthew J. Opperman1, Steven R. Barthel1,2, Danielle Hays1, Tobias Schatton1,3,
Qian Zhan4, Xiaoying He2,5, Khushi L. Matta6, Jeffrey G. Supko2,5, Markus H. Frank1,3, George F. Murphy2,4
and Charles J. Dimitroff1,2
Galectin-1 (Gal-1) has been shown to play a major role in tumor immune escape by inducing apoptosis
of effector leukocytes and correlating with tumor aggressiveness and disease progression. Thus, targeting the
Gal-1/Gal-1 ligand axis represents a promising cancer therapeutic approach. Here, to test the Gal-1-mediated
tumor immune evasion hypothesis and demonstrate the importance of Gal-1-binding N-acetyllactosamines in
controlling the fate and function of antitumor immune cells, we treated melanoma- or lymphoma-bearing mice
with peracetylated 4-fluoro-glucosamine (4-F-GlcNAc), a metabolic inhibitor of N-acetyllactosamine biosynth-
esis, and analyzed tumor growth and immune profiles. We found that 4-F-GlcNAc spared Gal-1-mediated
apoptosis of T cells and natural killer (NK) cells by decreasing their expression of Gal-1-binding determinants.
4-F-GlcNAc enhanced tumor lymphocytic infiltration and promoted elevations in tumor-specific cytotoxic
T cells and IFN-g levels, while lowering IL-10 production. Collectively, our data suggest that metabolic lowering
of Gal-1-binding N-acetyllactosamines may attenuate tumor growth by boosting antitumor immune cell levels,
representing a promising approach for cancer immunotherapy.
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INTRODUCTION
Galectin-1 (Gal-1), a soluble b-galactoside-binding lectin,
can function as a biological modifier of tumor growth and
metastasis (Andre et al., 1999; Jung et al., 2007; Rabinovich
et al., 2007; Rabinovich and Ilarregui, 2009). Gal-1 mediates
autocrine and paracrine activities that favor invasiveness
(Woynarowska et al., 1994, 1996; Clausse et al., 1999;
van den Brule et al., 2003), drives angiogenesis (Thijssen
et al., 2006), and regulates antitumor immune responses
(Rubinstein et al., 2004; Ilarregui et al., 2009; Stannard
et al., 2010). Gal-1 influences the fate and function of
effector leukocytes by inducing proapoptotic signals and
skewing cancer microenvironments toward T helper 2 (Th2)
profile and regulatory cytokine profiles (Juszczynski et al.,
2007; Ilarregui et al., 2009).
Considering recent studies targeting Gal-1 as anticancer
therapeutic strategies (Rubinstein et al., 2004; Ito et al., 2011;
Ouyang et al., 2011), we hypothesize that perturbing the
synthesis of Gal-1 carbohydrate-binding determinants (Gal-1
ligands) might interfere with Gal-1-mediated effects that
promote immune privilege of cancer. Gal-1 ligands are
membrane proteins with one or more N-acetyllactosamine
type 1 (Galb1, 3GlcNAc) or type 2 (Galb1, 4GlcNAc)
disaccharides on N-linked and O-linked glycans (Allen
et al., 1998; Karmakar et al., 2008). Gal-1 ligands are
expressed on activated lymphocytes and, upon their binding
to Gal-1, transmit proapoptotic signals or promote regula-
tory cytokine production (Perillo et al., 1995; Toscano et al.,
2007). Ligands identified to date include CD4, CD7, CD43,
and CD45 among others (Pace et al., 1999). Because
antitumor effector T cells express a high level of Gal-1
ligands, their viability and function is compromised in tumor
microenvironments rich in Gal-1. In fact, when tumor-
derived Gal-1 is abrogated, enhanced levels of IFN-g-
producing cells help prevent tumor progression (Rubinstein
et al., 2004; Ilarregui et al., 2009); similarly, when Gal-1
ligands (e.g., CD43) are absent, tumor growth is impaired
(Fuzii and Travassos, 2002).
Here, we show that limiting Gal-1 binding toN-acetyllactos-
amines on T-cell membrane proteins with a well-characterized
metabolic inhibitor ofN-acetyllactosamine synthesis, peracetyl-
ated 4-fluoro-glucosamine (4-F-GlcNAc) (Woynarowska et al.,
1994, 1996; Dimitroff et al., 2003b; Descheny et al., 2006;
Gainers et al., 2007; Barthel et al., 2011), attenuated growth of
B16 melanomas and EL-4 lymphomas through enhancement
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of antitumor immune responses. The 4-F-GlcNAc treatment
inhibited Gal-1-binding N-acetyllactosamine formation on
effector T cells and natural killer (NK) cells, which prevented
Gal-1-induced apoptosis and caused concomitant increases
in melanoma-specific cytotoxic T lymphocytes (CTLs) and
IFN-g levels. Overall, metabolic antagonism of Gal-1 ligand
formation strengthens the pharmacologic concept that inter-
fering with Gal-1/Gal-1 ligand axis could result in an
effective cancer immunotherapy.
RESULTS
Gal-1 and Gal-1 ligands are major determinants of host
immune response to melanoma
To validate the role of Gal-1 in tumor immune evasion,
we engineered B16 melanoma cell lines that overexpressed
Gal-1 (B16-Gal-1hi) or were silenced for Gal-1 expression
(B16-Gal-1KD). B16-Gal-1hi cells expressed 30% more Gal-1
than wild-type (wt) cells, and were characterized by a
Gal-1 molecule that is fused to a human immunoglobulin
Fc domain to impart constitutively active dimeric form
(Gal-1hFc) (Cedeno-Laurent et al., 2010) (Figure 1a and
Supplementary Figure S1a online). Conversely, B16-Gal-1KD
cells, produced by RNA interference, exhibited 95% less
Gal-1 (Figure 1a and Supplementary Figure S1a online).
Notably, all cell lines exhibited similar growth activity
(Supplementary Figure S1b online).
Subcutaneous inoculation into C57/BL6 mice demon-
strated B16-Gal-1hi tumor growth 41 cm3 within the first 15
days postinjection, whereas mice injected with B16-Gal-1KD
cells developed significantly smaller tumors (Po0.001;
Figure 1b). Importantly, B16-Gal-1KD and B16-Gal-1hi tumors
conserved their phenotype 15 days postinoculation (Supple-
mentary Figure S1c online). To determine the impact of Gal-1
ligands in controlling B16 melanoma growth, we performed
identical studies in mice lacking CD43, a putative Gal-1
ligand. CD43, a leukocyte membrane protein that displays
core 2 O-glycans upon T-cell activation (Daniels et al.,
2002), has been shown to favor Gal-1-mediated proapoptotic
activity and promote Gal-1-driven tolerogenic features on
antigen-presenting cells (Pace et al., 1999; Ilarregui et al.,
2009). CD43/ mice inoculated with B16-Gal-1hi cells
grew smaller tumors compared with wt mice (Po0.001),
but abrogation of tumor-derived Gal-1 did not show an
additive tumor-suppressive effect, suggesting that CD43 is an
important component of Gal-1-mediated immune escape
(Figure 1b). Alternatively, Gal-1/ mice inoculated with
B16-Gal-1hi tumors also developed smaller tumors than wt
mice, whereas those inoculated with B16-Gal-1KD exhibited
negligible growth (Po0.0001; Figure 1b), suggesting a role
for host-derived Gal-1 in tumor immune evasion. In all, B16-
Gal-1KD-draining lymph nodes (LNs) exhibited higher levels
of IFN-g-producing cells, and lower levels of IL-10 than found
in LNs draining B16-Gal-1hi tumors (Figure 1c). These effects
were more pronounced in CD43/ mice and Gal-1/ mice
(Figure 1d and e), suggesting that Gal-1 ligand expression and
host-derived Gal-1 are key components in the formation of
immune-privileged sites in cancer. Notably, in Rag2- and
Jak3-doubly deficient mice, which lack in B, T, and NK cells
(Barthel et al., 2009), tumors grew identically, independent
of their Gal-1 level (Figure 1f). These data suggest, as
similarly shown (Banh et al., 2011), that Gal-1-mediated
immune regulation plays a critical role in controlling tumor
growth juxtaposed to other protumorigenic activities, such as
angiogenesis.
A peracetylated 4-fluorinated analog of glucosamine disrupts
Gal-1 ligand synthesis sparing T cells from Gal-1-mediated
cell death
To determine whether lowering Gal-1 ligand expression
could avert Gal-1-mediated effects and boost antitumor
immunity, we utilized a DNFB-induced T-cell activation
model in mice treated with a fluorinated sugar analog of
N-acetyllactosamine biosynthesis, 4-F-GlcNAc. 4-F-GlcNAc
has been shown to inhibit N-acetyllactosamine and Gal-
1-binding determinant formation on membrane proteins
expressed by T cells (Barthel et al., 2011) and on ovarian
and colon cancer cells (Woynarowska et al., 1994, 1996;
Dimitroff et al., 2003a, b; Descheny et al., 2006; Gainers
et al., 2007). Stability analysis of 4-F-GlcNAc in mouse
plasma showed that the parent compound, fully acetylated
4-F-GlcNAc, exhibited a half-life ofB2.3 hours, sufficient for
uptake by relevant immune cells (Supplementary Figure S1d
online). Previous immunofluorescence analyses of DNFB-
draining LNs showed that nonactivated T cells did not bind
Gal-1, whereas robust Gal-1hFc staining was evident on T
cells expressing the early activation marker, CD69 (Cedeno-
Laurent et al., 2010). In contrast, we found here that Gal-1hFc
binding on activated T cells of 4-F-GlcNAc-treated mice was
markedly reduced, whereas the number of CD69þ cells
remained unchanged (Figure 2a). In all assays, use of lactose-
containing buffers confirmed b-galactoside-dependent
binding activity of Gal-1hFc. To assay whether inhibiting
Gal-1-binding N-acetyllactosamines with 4-F-GlcNAc also
prevented Gal-1-mediated apoptosis, T cells activated ex vivo
in the presence or absence of 4-F-GlcNAc were incubated
with Gal-1hFc with or without competitive inhibitor, lactose.
4-F-GlcNAc-treated T cells exhibited a significant reduction in
Gal-1-binding N-acetyllactosamines, and a marked resistance
to Gal-1-mediated apoptosis (Po0.001; Figure 2b–d).
4-F-GlcNAc treatment decreases melanoma growth and
reduces Gal-1 binding to T and NK cells
To ascertain whether 4-F-GlcNAc-dependent lowering
of Gal-1-binding N-acetyllactosamines on activated T cells
translated to enhanced antitumor immunity, mice were
inoculated with B16 wt cells and treated with 4-F-GlcNAc
or GlcNAc control for 17 days. Compared with control
treatment, 4-F-GlcNAc significantly inhibited tumor growth
(Figure 3a and b; Po0.001). In established tumors, 4-F-
GlcNAc treatment from days 9 to 17 also attenuated tumor
growth (Po0.001; Figure 3a). When 4-F-GlcNAc treatment
was evaluated in CD43- or Gal-1-deficient mice bearing B16
tumors, tumor growth was almost completely prevented
(Po0.01; Figure 3a and b). To validate 4-F-GlcNAc-mediated
enhancement of antitumor immune responses, we analyzed
the presence of tumor-infiltrating T cells by immunostaining
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formalin-fixed paraffin-embedded tumors with Gal-1hFc and
anti-CD3 mAb. Notably, control-treated mice showed mini-
mal tumor-lymphocytic infiltration (Figure 3c and Supple-
mentary Figure S1e online) with 90.4±3.1% of CD3þ cells
expressing Gal-1 ligands (Figure 3d and Supplementary
Figure S1e online). Conversely, 4F-GlcNAc-treated mice
exhibited 5.4-fold more tumor-infiltrating CD3þ cells
than control-treated mice (Figure 3c and Supplementary
Figure S1f online) and most T cells did not bind to Gal-1hFc
(18.3±6.4%; Figure 3d and Supplementary Figure S1f
online). To validate modification of Gal-1-binding N-acet-
yllactosamine expression on antitumor immunocytes of
4-F-GlcNAc-treated mice, tumor-draining LNs were harves-
ted and flow cytometry analyses revealed significant inhibi-
tion of Gal-1-binding determinants on T and NK cells
(*Po0.01 or **Po0.001; Figure 3e and Supplementary
Figure S2a online), and that lack of membrane protein
CD43 markedly lowered Gal-1 binding on both cell types
(Supplementary Figure S2a online).
4-F-GlcNAc-inhibitory efficacy on melanoma growth is driven
by higher levels of antimelanoma CTLs and lower levels of IL-10
To show that tumor-specific CTL death was reduced in 4-F-
GlcNAc-treated mice, we stained cells from tumor-draining
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Figure 1. Galectin-1 (Gal-1) and Gal-1 ligands promote melanoma immune evasion. (a) Gal-1 expression was quantified by quantitative reverse transcriptase-
PCR (qRT-PCR) in B16 Gal-1hi or B16 Gal-1KD cells. (b) Tumor growth (mean±SD) in mice inoculated with B16-Gal-1hi or B16-Gal-1KD cells (n¼15) was
assayed. Statistically significant differences compared with B16 Gal-1hi tumors grown in wild-type (wt) mice using Student’s paired t-test, **Po0.001 and
***Po0.0001. T cells from B16 Gal-1hi or B16 Gal-1KD-draining lymph nodes (LNs) were analyzed for IFN-g and IL-10 by flow cytometry (c) and are
graphically represented in d and e. Statistically significant differences compared with B16-Gal-1KD tumors using Student’s paired t-test, *Po0.01, **Po0.001.
(f) Tumor growth (mean±SD) was assayed in Rag2//Jak3/ mice (n¼ 15) inoculated with B16 Gal-1hi or B16 Gal-1KD cells. Experiments were repeated
3 times.
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LNs with a pentamer recognizing the B16-melanoma epitope
tyrosinase-related protein 2 (TRP-2; 180–188/H2Kb) TCR-
specific CTLs (Wells et al., 2008). Indeed, we found that
TRP-2-specific CTLs were elevated 2-fold compared with
GlcNAc control treatment, and that tumor-bearing CD43/
and Gal-1/ mice expressed 3-fold greater levels of TRP-2-
specific CTLs compared with control-treated wt mice
(Po0.01; Figure 4a and b and Supplementary Figure S2b
online), fortifying the role of Gal-1 in regulating antitumor
CTL levels. Additionally, we sorted nonnaive (CD62L) CTLs
from tumor-draining LNs, and co-cultured them ex vivo at
incremental ratios of carboxyfluorescein succinimidyl ester-
labeled B16 tumor cells. At 6 hours postexposure, we found
that CTLs from 4-F-GlcNAc-treated mice induced greater
tumor cytotoxicity, as determined by 7-amino-actinomycin D
uptake than controls (Po0.05; Figure 4c and Supplementary
Figure S2c online). Notably, increased cytotoxicity paralleled
the amount of CTLs present in the B16/T cell mixed culture,
whereas no significant tumor cell death was observed in
naive T-cell co-cultures (Figure 4c and Supplementary Figure
S2c online). These data suggested that attenuated B16
tumor growth rates in 4-F-GlcNAc-treated, Gal-1/, and/or
CD43/ mice correlated with higher levels of antitumor
CTLs.
To exclude whether 4-F-GlcNAc-dependent decrease in
N-acetyllactosamine synthesis could be altering tumor
growth by immune-independent mechanisms, we performed
identical experiments in Rag2//Jak3/ mice lacking B, T,
and NK cells, and found that B16 tumor growth rates were
identical (Supplementary Figure S2d online), suggesting that
altering Gal-1-binding N-acetyllactosamine synthesis on
effector antitumor immunocytes with 4-F-GlcNAc directly
translated into enhanced antitumor responses.
We and others have shown that Gal-1 not only promotes
apoptosis on effector immune cells, but can also promote
IL-10 cytokine secretion (Juszczynski et al., 2007; van der Leij
et al., 2007; Motran et al., 2008; Ilarregui et al., 2009;
Cedeno-Laurent et al., 2010). Therefore, we hypothesized
that by abrogating Gal-1-binding N-acetyllactosamine forma-
tion on effector T cells could prevent Gal-1-mediated IL-10
104
103
102
101
101 102 103 104
100
104
103
102
101
100
104
103
102
101
100
104
103
102
101
100
100
104
103
102
101
101 102 103 104
100
104
103
102
101
100
104
103
102
101
100
100 101 102 103 104100 101 102 103 104100
101 102 103 104100 101 102 103 104100 101 102 103 104100
4-F-GlcNAc
– +
Lactose control
CD69
3 25
70 2
1 9
74 16
1 2
72 25
G
al
-1
hF
c 
bi
nd
in
g
CD3
DNFB-
draining LNs
CD
4
Isotype
Lactose
4-F-GlcNAc
Untreated
Co
un
ts
Activated T cells
0
25
50
75
100
Untreated 4-F-GlcNAc Lactose
control
%
 A
nn
ex
in
+
/P
I+
**
***
104103102101100
Annexin V
PI
0 70
11 19
1 19
76 14
4-F-GlcNAc
1 2
95 2
Lactose controlGlcNAc control
Ex vivo–activated mouse CD4+ T cells
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production and perhaps increase levels of IFN-g, a key
determinant in T cell–directed antimelanoma responses
(Kortylewski et al., 2004; Rubinstein et al., 2004). Accord-
ingly, 17 days postinjection, we analyzed T-cell cytokine
profiles of B16 tumor-draining LNs in 4-F-GlcNAc- and
control-treated mice. Compared with control animals, 4-F-
GlcNAc-treated mice exhibited significantly higher levels of
IFN-gþ T cells (Po0.01; Figure 4d and Supplementary Figure
S2e and f online). Similar elevations in IFN-g were observed
in CD43- and Gal-1-deficient mice treated with 4-F-GlcNAc,
although baseline levels of IFN-g in control groups were
higher than those in wt mice (Figure 4d and Supplementary
Figure S2e and f online). In contrast, IL-10þ T cells were
significantly diminished in mice treated with 4-F-GlcNAc
(Po0.001; Figure 4d and Supplementary Figure S2g
online). Of note, the number of IL-10þ cells from control-
treated CD43- and Gal-1-deficient mice were markedly
decreased compared with wt mice (Figure 4d and Supple-
mentary Figure S2g online), confirming the role of both
molecules in Gal-1-mediated induction of IL-10 synthesis. In
addition, to rule out the possibility that 4-F-GlcNAc had a
cytotoxic effect on regulatory T cells, which produce IL-10,
we analyzed the expression of the transcription factor FoxP3
(forkhead box P3) in CD4þ T cells from tumor-draining LNs
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of 4-F-GlcNAc-treated mice and found no significant changes
in their level (Supplementary Figure S2h online).
4-F-GlcNAc treatment similarly inhibits lymphoma growth
by increasing IFN-cþ CTLs and lowering IL-10þ T cells
To strengthen observations of 4-F-GlcNAc efficacy on effector
antitumor immune cells and corresponding anti-B16 melanoma
activity, we performed identical experiments in mice bearing
Gal-1-expressing EL-4 lymphomas (Figure 5a). As expected,
there was a dramatic reduction in EL-4 tumor size in 4-F-
GlcNAc-treated (wt and Gal-1/) mice compared with those
in GlcNAc-treated mice (Po0.001; Figure 5b and c). We
found that T and NK cells from tumor-draining LNs showed
diminished expression of Gal-1-binding N-acetyllactosamines
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T cells from 4-F-GlcNAc-treated or control-treated melanoma-bearing mice were co-cultured with carboxyfluorescein succinimidyl ester (CFSE)-labeled B16
cells; after 6 hours, cells were stained with 7-amino-actinomycin D (7-AAD) and assayed for CFSEþ cell viability. (d) CD4þ and CD8þ T cells from melanoma-
draining LNs of 4-F-GlcNAc- or control-treated mice on day 17 were analyzed for IFN-g and IL-10 and are graphically represented from three different
experiments. Statistically significant difference compared with GlcNAc control group using Student’s paired t-test, *Po0.01 or **Po0.001.
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Figure 5. The 4-fluoro-glucosamine (4-F-GlcNAc) enhances antitumor immunity against EL-4 lymphomas. (a) Galectin-1 (Gal-1) expression on B16 and
EL-4 cells was confirmed by immunoblotting. Tumor masses (mean±SD) from (b) wild-type (wt) or (c) Gal-1/ mice treated with 4-F-GlcNAc or control
(n¼6 per group) are represented graphically. (d) Cells from EL-4-draining lymph nodes (LNs) were stained for CD4, CD8, NK1.1, and Gal-1 ligands.
(e) Cells from EL-4-draining LN cells were stained for CD4, CD8, IFN-g, and IL-10 and are graphically represented in f and g. (h) Sorted CD62L cytotoxic
T lymphocytes (CTLs) from 4-F-GlcNAc-treated or GlcNAc control-treated mice bearing EL-4 tumors (n¼ 5 per group) were co-cultured with carboxyfluorescein
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Statistically significant difference compared with GlcNAc controls using Student’s paired t-test, *Po0.01, **Po0.001. Experiments were repeated three times.
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after 4-F-GlcNAc treatment (Figure 5d), with concomitant
increased levels of IFN-g levels compared with control-
treated mice (Figure 5e and f). Conversely, IL-10þ T cells
were significantly diminished in 4-F-GlcNAc-treated wt and
in Gal-1/ mice (Po0.001; Figure 5e and f). Accordingly,
we observed enhanced tumor cytolytic activity in co-cultures
of EL-4 tumor cells and CTLs cells from tumor-draining LNs of
wt or Gal-1/ mice treated with 4-F-GlcNAc (Figure 5g).
These data corroborated the inhibitory effects of 4-F-GlcNAc
on B16 tumor growth and its stimulatory effects on effector
antitumor immunocyte levels.
DISCUSSION
Emerging evidence suggests that Gal-1 aids in establishing
immune privilege in cancer (Rubinstein et al., 2004). Gal-1
has been shown to hamper the vitality of effector T cells and
production of antitumor cytokine, IFN-g, while inducing the
expression of IL-10þ regulatory T cells (Kortylewski et al.,
2004; Rubinstein et al., 2004; Juszczynski et al., 2007). To
analyze the dependence of Gal-1-binding N-acetyllactos-
amines in Gal-1-mediated tumor immune evasion, we used a
fluoro-glucosamine inhibitor of N-acetyllactosamine forma-
tion, 4-F-GlcNAc. This inhibitor prevents N-acetyllactos-
amine synthesis on N- and O-glycans in glyco-metabolically
active immune cells and prevents consequent lectin-binding
activity with relatively high specificity for Gal-1-binding
determinants (Woynarowska et al., 1994, 1996; Dimitroff
et al., 2003a, b; Descheny et al., 2006; Gainers et al., 2007;
Barthel et al., 2011). Importantly, in this report, we show that
diminution of Gal-1 binding on activated T cells via 4-F-
GlcNAc treatment can alleviate Gal-1-mediated T-cell
apoptotic activity. This observation indicated that effector
antitumor T cells in 4-F-GlcNAc-treated mice could expand
without restriction from a Gal-1 checkpoint, favoring
effective antitumor immune activity.
To evaluate 4-F-GlcNAc-mediated antitumor efficacy in
mice bearing syngeneic tumors whose growth and progres-
sion is dependent on effector T-cell suppression controlled in
part by Gal-1 (Rubinstein et al., 2004), we treated tumor-
bearing mice with N-acetyllactosamine-lowering doses of
4-F-GlcNAc and used mice deficient in candidate Gal-1
ligand, CD43. We found that tumor growth was significantly
reduced and paralleled concomitant lower levels of Gal-1-
binding N-acetyllactosamine on effector T cells and NK cells,
elevations in IFN-gþ and melanoma-specific CTLs, and
reductions in IL-10þ T cells. Furthermore, increased tumor
cytolytic activity was observed on tumor cells co-cultured
with nonnaive CTLs from 4-F-GlcNAc-treated tumor-bearing
mice. Additionally, we found that established tumors were
also sensitive to 4-F-GlcNAc treatment, suggesting that
antitumor immunity can be stimulated even after effector
T-cell subset differentiation has been imprinted in tumor-
draining LNs. As Gal-1 has been shown to stimulate tumor
angiogenesis and enhance metastatic potential (Thijssen
et al., 2006, 2008, 2010), inhibition of Gal-1-binding
N-acetyllactosamine synthesis on tumor endothelial cells
could be a reason for suppressed tumor growth. However,
4-F-GlcNAc was ineffective at slowing tumor growth in
immunodeficient mice, implying that 4-F-GlcNAc-depen-
dent immune cell protection may be more influential than
on Gal-1-binding N-acetyllactosamine-dependent tumor
angiogenesis. This interpretation is supported by similar
observations recently made on a lung carcinoma mouse
model (Banh et al., 2011). Our collective results suggest
that (1) Gal-1-binding N-acetyllactosamines are targetable
moieties on effector T helper cells, CTLs, and NK cells; (2)
CD43 is one of the membrane proteins transmitting Gal-1-
mediated immunoregulation; and (3) 4-F-GlcNAc treatment
can interfere with N-acetyllactosamine formation to prevent
Gal-1-mediated apoptosis and raise the level of antitumor
immune cells.
Because tumor endothelial and stromal cells have also
been shown to express Gal-1, it is possible that host-derived
Gal-1 might contribute to facilitate tumor immune evasion
(Thijssen et al., 2006, 2008). To this end, we investigated
tumor growth in Gal-1/ mice. We show that tumor growth
was attenuated in Gal-1/ mice and, compared with wt
mice, displayed higher levels of IFN-g, melanoma-specific
CTLs, and suppressed expression of IL-10þ T cells. Of note,
when 4-F-GlcNAc treatment was included in tumor-bearing
Gal-1/ mice, the tumors were even smaller and effector
T-cell populations were higher, suggesting that to effectively
interfere with the Gal-1/Gal-1 ligand axis, Gal-1 from the
host and the tumor or all prospective Gal-1 ligands need to be
targeted to achieve maximal antitumor immune efficacy.
Because N-acetyllactosamines are key moieties for sialyl
Lewis X and platelet-/leukocyte- and endothelial-selectin
ligand formation, 4-F-GlcNAc treatment can also interfere
with the capacity of T cells to traffic to inflamed sites. Indeed,
4-F-GlcNAc can alleviate T-cell recruitment to inflamed skin
by interfering with endothelial-selectin ligand synthesis
(Dimitroff et al., 2003a, b; Descheny et al., 2006; Gainers
et al., 2007). In studies performed here, although we
demonstrate that Gal-1-binding N-acetyllactosamines are
significantly lowered on effector T cells following 4-F-
GlcNAc treatment, this inhibitory effect did not interfere
with the ability of these cells to traffic to tumors. Unlike
inflammation in the skin, which requires endothelial- and
platelet-selectin-binding activity on inflammatory leukocytes
(Staite et al., 1996; Catalina et al., 1999; Hirata et al., 2002),
the tumor vasculature, particularly in melanomas, does not
express endothelial-selectin or platelet-selectin (Weishaupt
et al., 2007). That is, 4-F-GlcNAc-treated tumor-infiltrating
T cells could mobilize to melanomas independent of endo-
thelial- and platelet-selectin-dependent binding activity and
elicit antitumor activity. Furthermore, recent data from our
laboratory indicate that endothelial-selectin-binding carbo-
hydrate determinants, which include N-acetyllactosamines
displayed by both membrane glycoproteins and glycolipids,
are more difficult to eliminate by 4-F-GlcNAc treatment
than Gal-1-binding N-acetyllactosamines, which are found
only on membrane glycoproteins (Barthel et al., 2011).
This is likely because of several observations showing that
4-F-GlcNAc treatment does not interfere with endothelial-
selectin-binding determinants and N-acetyllactosamine for-
mation on glycolipids (Dimitroff et al., 2003a, b; Descheny
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et al., 2006; Gainers et al., 2007; Barthel et al., 2011). In
addition, we have found that 4-F-GlcNAc treatment does not
greatly affect leukocyte-selectin ligand expression on high
endothelial venules and alter the distribution of pattern
of naive lymphocytes to secondary lymphoid organs
(Dimitroff et al., 2003b). Thus, endothelial cells do not
appear to be particularly sensitive to glycometabolic modula-
tion in vivo.
Interestingly, although N-acetyllactosamines can serve as
binding partners for other galectins, tumor growth in both
murine tumor models used in this report shows a high depen-
dency on Gal-1 expression. Nevertheless, data regarding the
protumorigenic activity of other proapoptotic b-galactoside-
binding lectins, such as Gal-9, remain controversial. Although
Gal-9 has been shown to enhance antitumor immunity via
dendritic cell and monocyte stimulation during early stages
of antitumor immune responses (Nagahara et al., 2008),
recent reports suggest that, at later phases, Gal-9 induces
T-cell exhaustion through T-cell immunoglobulin- and mucin-
domain-containing molecule 3 (TIM-3) signaling, favoring the
progression of solid and hematopoietic malignant tumors
(Sakuishi et al., 2010; Zhou et al., 2011).
In summary, this report highlights the critical role of Gal-1
in melanoma immunity and established that boosting
antitumor immune responses via modifications of Gal-1-
binding N-acetyllactosamines can be an effective mode of
cancer treatment.
MATERIALS AND METHODS
Mice, cell lines, antibodies, and chemicals
C57BL/6 wt mice and Gal-1/mice were obtained from the Jackson
Laboratory (Bar Harbor, ME). C57BL/6 CD43/ mice were kindly
provided by Dr Hermann J Ziltener (University of British Columbia,
British Columbia, Canada). Immunodeficient mice lacking B, T, and
NK cells that were deficient in Rag2 and Jak3 genes (Rag2//Jak3/)
were generated as described (Barthel et al., 2009). J558L plasma-
cytoma cells and EL-4 cells were purchased from American Type
Culture Collection (ATCC, Manassas, VA). All mouse experiments
were approved by the institutional animal care and use committee of
Harvard Center for Comparative Medicine. B16F10 melanoma cells
were a kind gift from Dr Hans Widlund (Brigham and Women’s
Hospital). Antibodies included: anti-mouse/human Gal-1 (N16) and
anti-mouse b-actin (Santa Cruz Biotechnology, Santa Cruz, CA);
anti-goat IgG (Southern Biotech, Birmingham, AL); anti-human Fc
(Jackson Immunoresearch, West Grove, PA); anti-mouse CD4, CD3,
CD8, CD16, CD19, CD69, NK1.1, IL-4, IL-10, IL-17, IFN-g,
Annexin-V, and propidium iodide (Biolegend, San Diego, CA); and
TRP-2 pentamer (Proimmune, Springfield, VA). 2-Acetamido-1,3,6-
tri-O-acetyl-4-deoxy-4-fluoro-D-glucopyranose, 4-F-GlcNAc, was
prepared as described (Sharma et al., 1990; Woynarowska et al.,
1994, 1996). N-acetylglucosamine was purchased from Sigma
Chemical (St Louis, MO).
Production of B16 melanoma Gal-1hi cells
B16 melanoma cells were transfected with a previously reported
plasmid encoding Gal-1hFc (Cedeno-Laurent et al., 2010). Gal-1hi
cells were selected in Zeocin, cloned, and analyzed for Gal-1
expression by western blot and real-time reverse transcriptase-PCR
using the primers: Gal-1 F: 50-TCTCAAACCTGGGGAATGTC-30, R:
50-GCGAGGATTGAAGTGTAGGC-30 and b-actin F: 50-CATCGTAC
TCCTGCTTGCTG-30, R 50-AGCGCAAGTACTCTGTGTGG-30. Sam-
ples were analyzed in triplicate and normalized to b-actin expression.
Production of B16 melanoma Gal-1KD cells by RNA silencing
The pLKO.1 vector encoding a short-hairpin RNA (shRNA) sequence
against mouse Gal-1 (NM_008495) or encoding a nonsilencing,
scrambled shRNA control sequence was obtained from the RNAi
Consortium (TRC) of the Broad Institute (MIT, Cambridge, MA) or
from Addgene (Cambridge, MA), respectively. B16 melanoma cells
were transduced with shRNA-expressing lentivirus and then further
selected. The target 21-mer sequence of mouse Gal-1 recognized by
the shRNA was: 50-CCTACACTTCAATCCTCGCTT-30. Gal-1 knock-
down was confirmed by western blot and by quantitative reverse
transcriptase-PCR analysis with the following primer sequences:
F, 50-TCTCAAACCTGGGGAATGTC-30, R, 50-GCGAGGATTGAAGT
GTAGGC-30.
Production of Gal-1hFc
Gal-1hFc and non-b-galactoside-binding mutant (dmGal-1hFc)
containing the non-Fc receptor FcgRI-binding variant (pFUSE-
hIgG1e3-Fc2; InvivoGen, San Diego, CA) were purified as described
(Cedeno-Laurent et al., 2010).
Gal-1 ligand expression analysis
Cells were analyzed for Gal-1 ligand expression using Gal-1hFc or
dmGal-1hFc as previously described (Cedeno-Laurent et al., 2010).
Experiments were performed in triplicate.
Treatment of mice bearing tumors with 4-F-GlcNAc
B16 melanoma cell variants were injected subcutaneously (2 105)
into the right flank of 6-week-old C57BL/6 wt, CD43/, Gal-1/,
or Rag2//Jak3/ mice (n¼ 15 for each group, 5 mice per
experiment). Tumor development was monitored as described
(Rubinstein et al., 2004). Intraperitoneal injections of 4-F-GlcNAc
or GlcNAc control (Sigma Chemical(each at 100mg kg–1) were
performed every other day starting on day 1 or day 9 postinjection.
Tumor-draining LNs were retrieved for FACS analysis.
Western blotting
Gal-1 and b-actin were immunoblotted as previously described
(Cedeno-Laurent et al., 2010).
In vivo T-cell activation
Abdominal skin of C57/B6 mice was painted on day 0 and day 1
with 25 ml of 0.5% DNFB (Sigma) in a 4:1 acetone/olive oil vehicle.
Mice were treated with 100mg kg–1 4-F-GlcNAc or GlcNAc control
on days 1, 3, and 5 postsensitization and LNs were harvested on day
6 for analysis by flow cytometry.
Pentamer staining
Tumor-draining LNs were harvested on day 17 and minced, and
single-cell suspensions were blocked with anti-mouse CD16 (FcRg)
(1:100) for 10minutes on ice and immediately stained with one-test
phycoerythrin-conjugated TRP-2 pentamers for 10minutes at room
temperature. Cells were further stained and negatively gated on
CD19 and CD8 mAbs.
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Tumor cytotoxicity assays
CD62L/CD8þ T cells from tumor-draining LNs were isolated from
4-F-GlcNAc-treated or control-treated mice 17 days posttumor
inoculation by immunomagnetic bead negative selection for
CD62L and positive selection for CD8þ T cells (Miltenyi Biotec,
Auburn, CA). Sorted CD62L/CD8þ T cells or naive CD4þ T cells
were plated at incremental ratios with B16 or EL-4 tumor cells
labeled with carboxyfluorescein succinimidyl ester in 96-well
round-bottom plates. After 6 hours of incubation, cells were stained
with 7-amino-actinomycin D for 10minutes and analyzed by flow
cytometry.
Statistical analyses. Statistical significance was ascertained
between two groups using Student’s paired t-test.
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